Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Department of Respiratory Medicine, King's College Hospital, London, UK.
BMJ Open Respir Res. 2019 Feb 18;6(1):e000363. doi: 10.1136/bmjresp-2018-000363. eCollection 2019.
The King's Brief Interstitial Lung Disease (KBILD) is a 15-item validated health-related quality of life (HRQOL) questionnaire. The method of scoring the KBILD has recently changed to incorporate a logit-scale transformation from one that used raw item responses, as this is potentially a more linear scale. The aim of this study was to re-evaluate the KBILD minimal clinically important difference (MCID) using the new logit -transformed scoring.
57 patients with interstitial lung disease (17 idiopathic pulmonary fibrosis, IPF) were asked to complete the KBILD questionnaire on two occasions in outpatient clinics. At the second visit, patients also completed a 15-item global rating of change of health status questionnaire (GRCQ). The MCID was calculated as the mean of four different methods: the change in KBILD for patients indicating a small change in GRCQ, patients with a 7%-12% change in FVC, 1 SE of measurement of baseline KBILD and effect size (ES) of 0.3.
The mean (SD) KBILD total score for all patients was 55.3 (15.6). 16 patients underwent a therapeutic intervention. 36 patients reported a change in their condition on the GRCQ; 22 deteriorated, 14 improved and 21 were unchanged. There was a significant change in KBILD total score in patients reporting a change in GRCQ; mean (SD) 57.0 (13.6) versus 50.0 (9.7); mean difference 7.0; 95% CI of difference 3.0 to 11.0; p<0.01. The change in KBILD total score correlated with the GRCQ scale; r=-0.49, p<0.01. The mean KBILD total score MCID was 5. The MCID of KBILD domains were 6 for Psychological, 7 for Breathlessness and Activities, and 11 for Chest Symptoms.
The KBILD is a responsive tool for longitudinal assessment of HRQOL in patients with ILD. The MCID of the KBILD total score is a 5-unit change.
金氏简要间质性肺病（KBILD）是一个包含 15 个项目的经过验证的健康相关生活质量（HRQOL）问卷。最近，KBILD 的评分方法发生了变化，采用了对数尺度转换，而不是以前使用的原始项目反应，因为这是一种更线性的尺度。本研究的目的是使用新的对数转换评分重新评估 KBILD 的最小临床重要差异（MCID）。
57 名间质性肺病（ILD）患者（17 名特发性肺纤维化，IPF）在门诊接受了两次 KBILD 问卷调查。在第二次就诊时，患者还完成了一份 15 项健康状况总体变化全球评分问卷（GRCQ）。MCID 是通过四种不同方法的平均值计算得出的：GRCQ 显示健康状况小变化的患者的 KBILD 变化，FVC 变化 7%-12%的患者，基线 KBILD 的 1 SE 测量值和效应量（ES）为 0.3。
所有患者的 KBILD 总分平均值（标准差）为 55.3（15.6）。16 名患者接受了治疗干预。36 名患者报告了 GRCQ 中的病情变化；22 名恶化，14 名改善，21 名不变。报告 GRCQ 变化的患者的 KBILD 总分有显著变化；平均值（标准差）为 57.0（13.6）与 50.0（9.7）；平均差异 7.0；95%置信区间差值为 3.0 至 11.0；p<0.01。KBILD 总分的变化与 GRCQ 量表相关；r=-0.49，p<0.01。KBILD 总分的 MCID 平均值为 5。KBILD 各领域的 MCID 分别为心理领域 6，呼吸困难和活动领域 7，胸部症状领域 11。
KBILD 是一种用于评估ILD 患者 HRQOL 的纵向反应工具。KBILD 总分的 MCID 是 5 个单位的变化。
